View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
TUESDAY, Oct. 20 (HealthDay News) -- Patients with stable ischemic heart disease and preserved ventricular function may benefit from angiotensin-converting enzyme (ACE) inhibitors, according to a review published online Oct. 20 in the Annals of Internal Medicine.
William L. Baker, of Hartford Hospital in Connecticut, and colleagues reviewed the results of 41 trials that evaluated the efficacy and adverse effects of ACE inhibitors, angiotensin II-receptor blockers (ARBs), and combination therapy in individuals with stable ischemic heart disease and preserved ventricular function.
Considering the seven trials with moderate- to high-strength evidence involving 32,559 patients, the researchers found that ACE inhibitors were associated with a lower risk of total mortality and nonfatal myocardial infarction, but with an increased risk of syncope and cough compared with placebo. One trial of moderate strength evidence involving 25,620 patients showed that, compared with ACE inhibitors alone, treatment with ARBs plus ACE inhibitors was associated with a slightly higher risk of total mortality, myocardial infarction, and discontinuations due to hypotension and syncope.
"Adding an ACE inhibitor to standard medical therapy improves outcomes, including mortality and myocardial infarctions, in some patients with stable ischemic heart disease and preserved ventricular function," the authors conclude. "Combination therapy seems no better than ACE inhibitor therapy alone and increases harms."
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top